Ginkgo Bioworks Holdings Yönetim
Yönetim kriter kontrolleri 3/4
Ginkgo Bioworks Holdings CEO'su Jason Kelly, Jan2008 tarihinde atandı, in görev süresi 16.83 yıldır. in toplam yıllık tazminatı $ 262.50K olup, şirket hissesi ve opsiyonları dahil olmak üzere 95.2% maaş ve 4.8% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.84% ine doğrudan sahiptir ve bu hisseler $ 13.43M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.3 yıl ve 1.5 yıldır.
Anahtar bilgiler
Jason Kelly
İcra Kurulu Başkanı
US$262.5k
Toplam tazminat
| CEO maaş yüzdesi | 95.2% |
| CEO görev süresi | 16.8yrs |
| CEO sahipliği | 3.8% |
| Yönetim ortalama görev süresi | 6.3yrs |
| Yönetim Kurulu ortalama görev süresi | 1.5yrs |
Son yönetim güncellemeleri
Recent updates
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
Nov 15
Ginkgo Bioworks: Not Enough Progress
Nov 13Revenues Tell The Story For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) As Its Stock Soars 33%
Oct 04Ginkgo Bioworks: Here Comes The Test
Aug 22The Price Is Right For Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Even After Diving 27%
Aug 16Ginkgo Bioworks: Losing A Major Supporter
Jun 25Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 47% Slump
Jun 18Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
May 11Ginkgo Bioworks: Broken Narrative
May 10Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
Apr 26Newsflash: Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Analysts Have Been Trimming Their Revenue Forecasts
Mar 06With Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) It Looks Like You'll Get What You Pay For
Mar 01Ginkgo Bioworks: More Awful Revenue Guidance
Mar 01Ginkgo Bioworks At The Intersection Of Cutting-Edge Technology And Financial Disappointment
Jan 26Ginkgo Bioworks: Strategic Shifts Amidst Financial Uncertainty
Dec 20Ginkgo Bioworks: A Long Way To Go
Nov 21News Flash: 9 Analysts Think Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Earnings Are Under Threat
Nov 13Ginkgo Bioworks: More Revenue Issues
Nov 13Ginkgo Bioworks Holdings, Inc.'s (NYSE:DNA) Share Price Is Still Matching Investor Opinion Despite 30% Slump
Nov 10Porter's 5 Forces Suggest That Ginkgo Is A Buy
Oct 25Ginkgo Bioworks: Products Progressing Towards Market
Oct 10Ginkgo Bioworks: Google Partnership Increases Runway (Rating Upgrade)
Aug 30Ginkgo Bioworks: Lack Of Progress Is A Concern
Aug 18Ginkgo Bioworks: Major Revenue Trouble (Ratings Downgrade)
Aug 10Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds
Jun 23Ginkgo Bioworks: Avoid For Now
Feb 20Ginkgo: Standardizing Offerings For Growth
Feb 08Ginkgo Bioworks: Increasing Focus On Pharma And Biotech
Jan 12CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$651m |
| Jun 30 2024 | n/a | n/a | -US$898m |
| Mar 31 2024 | n/a | n/a | -US$854m |
| Dec 31 2023 | US$263k | US$250k | -US$893m |
| Sep 30 2023 | n/a | n/a | -US$857m |
| Jun 30 2023 | n/a | n/a | -US$1b |
| Mar 31 2023 | n/a | n/a | -US$2b |
| Dec 31 2022 | US$263k | US$250k | -US$2b |
| Sep 30 2022 | n/a | n/a | -US$4b |
| Jun 30 2022 | n/a | n/a | -US$3b |
| Mar 31 2022 | n/a | n/a | -US$2b |
| Dec 31 2021 | US$381m | US$250k | -US$2b |
| Sep 30 2021 | n/a | n/a | -US$276m |
| Jun 30 2021 | n/a | n/a | -US$200m |
| Mar 31 2021 | n/a | n/a | -US$175m |
| Dec 31 2020 | US$11m | US$250k | -US$127m |
Tazminat ve Piyasa: Jason 'nin toplam tazminatı ($USD 262.50K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 2.18M ).
Tazminat ve Kazançlar: Jason 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Jason Kelly (43 yo)
16.8yrs
Görev süresi
US$262,500
Tazminat
Dr. Jason Kelly serves as Director of Genomatica, Inc. Dr. Kelly founded Ginkgo Bioworks, Inc. (nka:Ginkgo Bioworks Holdings, Inc.) in 2008 and serves as its Chief Executive Officer and has been Director s...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 16.8yrs | US$262.50k | 3.84% $ 13.4m | |
| Founder | 16.8yrs | US$262.50k | 4.18% $ 14.6m | |
| Chief Financial Officer | 4yrs | US$1.69m | 0.084% $ 295.3k | |
| Founder | no data | Veri yok | Veri yok | |
| Founder | no data | Veri yok | 4.28% $ 15.0m | |
| Founder | no data | Veri yok | 4.17% $ 14.6m | |
| Chief Accounting Officer | 1.5yrs | Veri yok | 0.012% $ 40.5k | |
| General Counsel & Secretary | no data | Veri yok | Veri yok | |
| Senior Vice President of Corporate Development | no data | Veri yok | Veri yok | |
| Head of People | 6.8yrs | Veri yok | Veri yok | |
| Head of Design | 6.1yrs | Veri yok | Veri yok | |
| Head of Omics & Analytical Chemistry | 6.3yrs | Veri yok | Veri yok |
6.3yrs
Ortalama Görev Süresi
43yo
Ortalama Yaş
Deneyimli Yönetim: DNA 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.3 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Founder | 16.8yrs | US$262.50k | 3.84% $ 13.4m | |
| Founder | 16.8yrs | US$262.50k | 4.18% $ 14.6m | |
| Member of Biopharma Advisory Board | less than a year | Veri yok | Veri yok | |
| Member of Biopharma Advisory Board | less than a year | Veri yok | Veri yok | |
| Independent Director | 3.2yrs | US$459.38k | 0.037% $ 129.3k | |
| Member of Biopharma Advisory Board | less than a year | Veri yok | Veri yok | |
| Independent Director | 8.8yrs | US$477.50k | 0.060% $ 210.3k | |
| Independent Director | 2.3yrs | US$448.67k | 0.0075% $ 26.2k | |
| Member of Biopharma Advisory Board | less than a year | Veri yok | Veri yok | |
| Independent Chairman of the Board | 9.8yrs | US$485.19k | 0.11% $ 386.5k | |
| Member of Biopharma Advisory Board | less than a year | Veri yok | Veri yok | |
| Member of Biopharma Advisory Board | less than a year | Veri yok | Veri yok |
1.5yrs
Ortalama Görev Süresi
59.5yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: DNA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.5 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.